LETTER TO THE EDITOR
Comment on comorbidities in older patients with myasthenia gravis
Giuliana Galassi,
Corresponding Author
Giuliana Galassi
Department of Biomedical, Metabolic Neural Sciences, University of Modena, Modena, Italy
Correspondence
Giuliana Galassi, Department of Biomedical, Metabolic Neural Sciences, University of Modena, Modena, Italy.
Email: [email protected]
Search for more papers by this author
Giuliana Galassi,
Corresponding Author
Giuliana Galassi
Department of Biomedical, Metabolic Neural Sciences, University of Modena, Modena, Italy
Correspondence
Giuliana Galassi, Department of Biomedical, Metabolic Neural Sciences, University of Modena, Modena, Italy.
Email: [email protected]
Search for more papers by this author
First published: 20 March 2022
No abstract is available for this article.
CONFLICT OF INTEREST
The author have no conflict of interest.
DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
REFERENCES
- 1Klimiec-Moskal E, Quirke M, Leite MI. Comorbidities in older patients with myasthenia gravis - comparison between early- and late-onset disease. Acta Neurol Scand. 2021; 145(3): 371-374. doi:10.1111/ane.13549
- 2Deymeer F. Myasthenia gravis: MuSK MG, late-onset MG and ocular MG. Acta Myol. 2020; 39: 345-352. doi:10.36185/2532-1900-038
- 3Li Y, Dong X, Li Z, et al. Characteristics of myasthenia gravis in elderly patients: a retrospective study. Neurol Sci. 2021. doi: 10.1007/s10072-021-05599-z
- 4Cortés-Vicente E, Álvarez-Velasco R, Segovia S, et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. 2020; 94(11): e1171-e1180. doi:10.1212/WNL.0000000000008903
- 5Melzer N, Ruck T, Gold R, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German neurological society. J Neurol. 2016; 263: 1473-1494. doi:10.1007/s00415-016-8045-z
- 6Murthy JMK. Myasthenic crisis - comorbidities, complications, long-term outcomes: the challenges. Ann Indian Acad Neurol. 2019; 22: 472-473. doi:10.4103/aian.AIAN_472_19
- 7Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015; 14: 1023-1036. doi:10.1016/S1474-4422(15)
- 8Vijayan J, Menon D, Barnett C, et al. Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis. Muscle Nerve. 2021; 64: 462-466. doi:10.1002/mus.27369
- 9Misra UK, Kalita J, Singh VK, Kumar S. A study of comorbidities in myasthenia gravis. Acta Neurol Belg. 2020; 120: 59-64. doi:10.1007/s13760-019-01102-w
- 10Vadasz Z, Haj T, Kessel A, Toubi E. Age-related autoimmunity. BMC Med. 2013; 11: 94. doi:10.1186/1741-7015-11-94
